Publication Feature: Does pharma innovation require high drug prices?

October 2019

Is the tradeoff between drug prices and innovative new therapies a zero-sum game, or can other things besides profits incentivize biopharma companies and investors? In the Health Affairs blog, Rena Conti of Questrom School of Business at Boston University and CRS contributor Frank David of Pharmagellan review the evidence linking pharmaceutical prices to innovation, and make the case for more research and experimentation on how to use non-price incentives to spur clinically meaningful R&D.

Read the full article here